SynthesisFrontiers in immunology2026
Controlling nutritional status score predicts clinical outcome in cancer patients treated with immune checkpoint inhibitor: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors.International journal of molecular sciences · 2026Review
- Association of controlling nutritional status with fecal incontinence and fecal incontinence severity index in individuals with spinal cord injury: mediating roles of interleukin-6 and uric acid.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the association between pretreatment controlling nutritional status (CONUT) score and clinical outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs). Methods: We conducted a comprehensive literature search of PubMed, Web of Science, Medline and Embase from inception of the databases to November 2025 to identify eligible studies concerning the relationship between pretreatment CONUT and survival outcomes in cancer patients treated with ICIs. Published data were extracted and risk ratio (RR) for objective response rate (ORR), disease control rate (DCR), and hazard ratio (HR) for overall survival (OS), progressive-free survival (PFS), along with 95% confidence intervals (CIs) were pooled. Data were analyzed using Stata14.0 software. Results: Ten studies involving 747 participants were included in this study. Patients were divided into low CONUT group and high CONUT group according to the cut-off value of CONUT score. Patients in high CONUT group had worse ORR and DCR than those in low CONUT group (RR 1.39, 95%CI 1.04-1.86;RR 1.64, 95%CI 1.32-2.03). Patients in high CONUT group had shorter PFS and OS than those in low CONUT group (1.71, 95%CI 1.21-2.42; 1.95, 95%CI 1.21-3.14). Subgroup analysis of cut-off value showed that PFS and OS of patients in high CONUT group were significantly shorter with a cut-off value of 3, and PFS of patients in high CONUT group were also worse than those of patients in the low CONUT group. Subgroup analysis of country indicated that both patients from Japan in high CONUT group had worse PFS and OS than those in low CONUT group, the OS of patients from China in high CONUT group was shorter than those in low CONUT group. Conclusion: The CONUT score has potential value as an effective biomarker for the efficacy and prognosis of cancer patients treated with ICIs. In the future, large-scale prospective cohort studies should be conducted to determine the optimal cut-off value of CONUT, and to explore whether early and proactive nutritional and anti-inflammatory support based on CONUT score can reverse the adverse prognosis. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022378362, identifier CRD42022378362.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.